Jasper Therapeutics, Inc. (JSPR)
NASDAQ: JSPR · Real-Time Price · USD
1.050
-0.060 (-5.41%)
At close: Mar 27, 2026, 4:00 PM EDT
1.055
+0.005 (0.47%)
After-hours: Mar 27, 2026, 6:17 PM EDT

Jasper Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Selling, General & Admin
21.8120.4217.0816.5711.414.8
Research & Development
71.5255.8251.7934.6325.4215.88
Total Operating Expenses
93.3376.2468.8651.236.8320.68
Operating Income
-93.33-76.24-68.86-51.2-36.83-20.68
Interest Income
2.345.065.20.7--
Total Non-Operating Income (Expense)
2.345.065.20.7--
Pretax Income
-90.99-71.18-63.66-50.5-36.83-20.68
Net Income
-90.99-71.18-63.66-50.5-36.83-20.68
Net Income to Common
-90.99-71.18-63.66-50.5-36.83-20.68
Shares Outstanding (Basic)
161510411
Shares Outstanding (Diluted)
161510411
Shares Change (YoY)
14.04%39.72%186.15%220.19%85.99%-55.72%
EPS (Basic)
-5.90-4.89-6.18-10.33-26.90-51.70
EPS (Diluted)
-5.90-4.89-6.18-10.33-26.90-51.70
Free Cash Flow
-76.53-63.15-52.33-46.43-36.11-18.27
Free Cash Flow Per Share
-4.94-4.33-5.01-12.73-31.69-29.82
EBITDA
-92.32-74.87-67.75-50.22-36.46-20.66
EBIT
-93.33-76.24-68.86-51.2-36.83-20.68
Updated Nov 10, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q